RU 28965 IN SUPERFICIAL PYOGENIC DISEASES

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement4; pp. 534 - 537
• Main Authors: SOMA, YOSHINAO, OGAWA, KIMIKO, YUN, KOICHI, YUN, SHUKUKA, HARADA, SHOTARO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988; 公益社団法人 日本化学療法学会
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement4_534

The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial pyogenic diseases. The results are presented here. RU 28965 was administered twice daily before morning and evening meals at 200-400mg for 3-15 consecutive days. The final general improvement was evaluated the day after the initial administration. Clinical effect in 19 patients (excluding one who did not return to the hospital after the administration) was: complete cure 16, remarkable improvement 1, and mild improvement 2. The efficacy rate (mild improvement or better) was 100%. Most of the isolates were staphylococci, and the disappearance rate of bacteria was 86.7%. As side-effects of the drug, angular stomatitis was observed in one case. Since this was mild and did not require treatment, the regimen was continued. As to utility of the drug, it was extremely useful in 14 cases, useful in 3, fairly useful in 1 and not useful in 1 case, with a utility rate of 89.5%.